Measuring patient experiences in fabry disease: validation of the Fabry Outcome Survey (FOS) paediatric health and pain questionnaire
Uma Ramaswami(The Royal Free Hospital), Donald E. Stull(IQVIA (United States)), Mireia Raluy(United BioSource Corporation (United Kingdom)), Guillem Pintos‐Morell(Hospital Universitari Germans Trias i Pujol), Gisela Kalkum(Johannes Gutenberg University Mainz), Ingela Wiklund(St George's, University of London), Marianne Rohrbach(Ghent University Hospital), Michael Beck(Eastern Illinois University), Catharina Whybra(Johannes Gutenberg University Mainz)
Cited by 1
Related Papers
Development and first validation of the COPD Assessment Test
|European Respiratory Journal|2009|3.2k
The 2017 international classification of the Ehlers–Danlos syndromes
|American Journal of Medical Genetics Part C Seminars in Medical Genetics|2017|1.9k
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
|European Journal of Pediatrics|2007|535
Optimal recall periods for patient-reported outcomes: challenges and potential solutions
|Current Medical Research and Opinion|2009|413
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
|The Journal of Pediatrics|2006|364